Last 12 months
Inside the activity.
4 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 2 | 0 |
| Jul 2026 | 2 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2020 Filed Jun 19, 2020 20:16 UTC |
BRANCACCIO JOHN PDirector
|
GrantStock Options · Derivative | 28,858 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-20-075238 · a4.xml · derivative · entry 1 BRANCACCIO JOHN P · CIK 0001276551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,517 Underlying: Common Stock · 28,858 shares Expires 2030-06-17 Read SEC document |
| May 14, 2020 Filed May 18, 2020 16:17 UTC |
Erlander MarkChief Executive Officer
|
PurchaseCommon Stock | 6,993 | $1.43 | $9,999.99 |
DisclosureSEC source: 0001104659-20-063184 · a4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,369 Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:16 UTC |
JACOB GARY SDirector
|
PurchaseCommon Stock | 17,483 | $1.43 | $25,000.69 |
DisclosureSEC source: 0001104659-20-063177 · a4.xml · nonDerivative · entry 1 JACOB GARY S · CIK 0001266802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,552 Read SEC document |
| May 14, 2020 Filed May 18, 2020 16:15 UTC |
ADAMS THOMAS PHDDirector
|
PurchaseCommon Stock | 13,986 | $1.43 | $19,999.98 |
DisclosureSEC source: 0001104659-20-063173 · a4.xml · nonDerivative · entry 1 ADAMS THOMAS PHD · CIK 0001234366 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,875 Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:16 UTC |
Markin Rodney SDirector
|
PurchaseCommon Stock | 20,979 | $1.43 | $29,999.97 |
DisclosureSEC source: 0001104659-20-063181 · a4.xml · nonDerivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Fund Disclosed balance after: 28,160 F1 · ownership.nature: Through Prairie Ventures, LLC Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:16 UTC |
BRANCACCIO JOHN PDirector
|
PurchaseCommon Stock | 6,993 | $1.43 | $9,999.99 |
DisclosureSEC source: 0001104659-20-063179 · a4.xml · nonDerivative · entry 1 BRANCACCIO JOHN P · CIK 0001276551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,260 Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:16 UTC |
White LaleDirector
|
PurchaseCommon Stock | 69,930 | $1.43 | $99,999.90 |
DisclosureSEC source: 0001104659-20-063176 · a4.xml · nonDerivative · entry 1 White Lale · CIK 0001635493 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 69,930 Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:15 UTC |
Armitage James ODirector
|
PurchaseCommon Stock | 10,490 | $1.43 | $15,000.70 |
DisclosureSEC source: 0001104659-20-063174 · a4.xml · nonDerivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,490 Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:16 UTC |
PACE GARY WDirector
|
PurchaseCommon Stock | 447,761 | $1.34 | $599,999.74 |
DisclosureSEC source: 0001104659-20-060862 · a4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 447,761 Read SEC document |
| April 16, 2020 Filed May 1, 2020 20:17 UTC |
PACE GARY WDirector
|
GrantStock Options · Derivative | 11,916 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001104659-20-055492 · a4.xml · derivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,916 Underlying: Common Stock · 11,916 shares Expires 2030-04-16 F1 · derivative.exercise_date: 3,972 of the Stock Options vest on each of 4/16/2021, 2022 and 2023 Read SEC document |
| April 16, 2020 Filed May 1, 2020 20:17 UTC |
Armitage James ODirector
|
GrantStock Options · Derivative | 11,916 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001104659-20-055491 · a4.xml · derivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,916 Underlying: Common Stock · 11,916 shares Expires 2030-04-16 F1 · derivative.exercise_date: 3,972 of the Stock Options vest on each of 4/16/2021, 2022 and 2023 Read SEC document |
| April 16, 2020 Filed May 1, 2020 20:16 UTC |
White LaleDirector
|
GrantStock Options · Derivative | 11,916 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001104659-20-055489 · a4.xml · derivative · entry 1 White Lale · CIK 0001635493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,916 Underlying: Common Stock · 11,916 shares Expires 2030-04-16 F1 · derivative.exercise_date: 3,972 of the Stock Options vest on each of 4/16/2021, 2022 and 2023 Read SEC document |
| January 03, 2020 Filed Jan 3, 2020 16:15 UTC |
Erlander MarkChief Scientific Officer
|
Tax withholdingCommon Stock | 116 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-000881 · a4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,376 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 116 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2020. Read SEC document |
| January 03, 2020 Filed Jan 3, 2020 16:10 UTC |
Erlander MarkChief Scientific Officer
|
Tax withholdingCommon Stock | 552 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-000872 · a4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,231 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 552 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January l, 2020. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 16:15 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 261 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-000881 · a4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260 Underlying: Common Stock · 261 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. The common stock into which such vested restricted stock units converted on January 2, 2020 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. The common stock into which such vested restricted stock units converted on January 2, 2020 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 16:15 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionCommon Stock | 261 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-000881 · a4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 16:10 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-000872 · a4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on January 1, 2020. The common stock into which such vested restricted stock units converted on January 1, 2020 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on January 1, 2020. The common stock into which such vested restricted stock units converted on January 1, 2020 is reported in Table I on this Form 4. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 16:10 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-000872 · a4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on January 1, 2020. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 16:16 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-052973 · a4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,771 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on October 1, 2019. The common stock into which such vested restricted stock units converted on October 1, 2019 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on October 1, 2019. The common stock into which such vested restricted stock units converted on October 1, 2019 is reported in Table I on this Form 4. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 16:16 UTC |
Erlander MarkChief Scientific Officer
|
Tax withholdingCommon Stock | 466 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-052973 · a4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,533 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 466 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on October l, 2019. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 16:16 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-052973 · a4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on October 1, 2019. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 06:21 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019005 · doc4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,021 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on July 1, 2019. The common stock into which such vested restricted stock units converted on July 1, 2019 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on July 1, 2019. The common stock into which such vested restricted stock units converted on July 1, 2019 is reported in Table I on this Form 4. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 06:21 UTC |
Erlander MarkChief Scientific Officer
|
Tax withholdingCommon Stock | 461 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019005 · doc4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,749 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 461 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on July l, 2019. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 06:21 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019005 · doc4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on July 1, 2019. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 16:06 UTC |
Erlander MarkChief Scientific Officer
|
GrantStock Options · Derivative | 134,203 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-19-017920 · doc4.xml · derivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,959 Underlying: Common Stock · 134,203 shares Expires 2029-06-20 F1 · derivative.exercise_date: 44,734 vest on each of 6/20/2020 and 2021 and 44,735 vest on 6/20/2022 Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 16:07 UTC |
ADAMS THOMAS PHDDirector · Chief Executive Officer
|
GrantStock Options · Derivative | 298,230 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-19-017922 · doc4.xml · derivative · entry 1 ADAMS THOMAS PHD · CIK 0001234366 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,725 Underlying: Common Stock · 298,230 shares Expires 2029-06-20 F1 · derivative.exercise_date: 99,410 vest on each of June 20, 2020, 2021 and 2022. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 20:07 UTC |
JACOB GARY SDirector
|
GrantStock Options · Derivative | 44,734 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-19-017923 · doc4.xml · derivative · entry 1 JACOB GARY S · CIK 0001266802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,071 Underlying: Common Stock · 44,734 shares Expires 2019-06-20 Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 20:06 UTC |
Markin Rodney SDirector
|
GrantStock Options · Derivative | 44,734 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-19-017921 · doc4.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,969 Underlying: Common Stock · 44,734 shares Expires 2029-06-20 Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 20:05 UTC |
Countouriotis AthenaDirector
|
GrantStock Options · Derivative | 44,734 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-19-017916 · doc4.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,019 Underlying: Common Stock · 44,734 shares Expires 2029-06-20 Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 20:05 UTC |
BRANCACCIO JOHN PDirector
|
GrantStock Options · Derivative | 44,734 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-19-017915 · doc4.xml · derivative · entry 1 BRANCACCIO JOHN P · CIK 0001276551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,806 Underlying: Common Stock · 44,734 shares Expires 2029-06-20 Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:00 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-009746 · doc4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,271 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on April 1, 2019. The common stock into which such vested restricted stock units converted on April 1, 2019 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on April 1, 2019. The common stock into which such vested restricted stock units converted on April 1, 2019 is reported in Table I on this Form 4. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:00 UTC |
Erlander MarkChief Scientific Officer
|
Tax withholdingCommon Stock | 459 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-009746 · doc4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,960 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 459 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on April 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:00 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-009746 · doc4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on April 1, 2019. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:10 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000518 · doc4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,125 Underlying: Common Stock · 1,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On January 4,2017, the reporting person was granted 6,250 restricted stock units, 1,563 of which vested on January 2, 2019. The common stock into which such vested restricted stock units converted on January 2, 2019 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On January 4,2017, the reporting person was granted 6,250 restricted stock units, 1,563 of which vested on January 2, 2019. The common stock into which such vested restricted stock units converted on January 2, 2019 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:10 UTC |
Erlander MarkChief Scientific Officer
|
Tax withholdingCommon Stock | 698 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000518 · doc4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,010 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 698 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:10 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionCommon Stock | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000518 · doc4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 4, 2017, the reporting person was granted 6,250 restricted stock units, 1,563 of which vested on January 2, 2019. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 16:05 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000506 · doc4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,688 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on January 1, 2019. The common stock into which such vested restricted stock units converted on January 1, 2019 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on January 1, 2019. The common stock into which such vested restricted stock units converted on January 1, 2019 is reported in Table I on this Form 4. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 16:05 UTC |
Erlander MarkChief Scientific Officer
|
Tax withholdingCommon Stock | 3,035 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000506 · doc4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,145 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 3,035 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 1, 2019. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 16:05 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000506 · doc4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on January 1, 2019. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 17:09 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-026063 · doc4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,188 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on October 1, 2018. The common stock into which such vested restricted stock units converted on October 1, 2018 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on October 1, 2018. The common stock into which such vested restricted stock units converted on October 1, 2018 is reported in Table I on this Form 4. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 17:09 UTC |
Erlander MarkChief Scientific Officer
|
Tax withholdingCommon Stock | 2,731 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-026063 · doc4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,680 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 2,731 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on October 1, 2018. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 17:09 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-026063 · doc4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on October 1, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 16:30 UTC |
Erlander MarkChief Scientific Officer
|
GrantRestricted Stock Units · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020661 · doc4.xml · derivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,688 Underlying: Common Stock · 45,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F2 · derivative.exercise_date: 7,500 of the RSUs will vest on each of October 1, 2018, January 1, 2019, April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020. F2 · derivative.expiration_date: 7,500 of the RSUs will vest on each of October 1, 2018, January 1, 2019, April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 20:30 UTC |
Markin Rodney SDirector
|
PurchaseCommon Stock | 41,200 | $0.85 | $35,020.00 |
DisclosureSEC source: 0000899243-18-017592 · doc4.xml · nonDerivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,810 Read SEC document |
| June 20, 2018 Filed Nov 9, 2018 21:30 UTC Amendment |
Markin Rodney SDirector
|
PurchaseCommon Stock | 41,200 | $0.85 | $35,020.00 |
DisclosureSEC source: 0000899243-18-028597 · doc4a.xml · nonDerivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,085 Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 10:03 UTC |
BRANCACCIO JOHN PDirector
|
PurchaseCommon Stock | 10,000 | $0.80 | $8,000.00 |
DisclosureSEC source: 0000899243-18-015836 · doc4.xml · nonDerivative · entry 1 BRANCACCIO JOHN P · CIK 0001276551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,167 Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 10:03 UTC |
Tennant StanleyDirector
|
PurchaseCommon Stock | 10,000 | $0.80 | $8,000.00 |
DisclosureSEC source: 0000899243-18-015835 · doc4.xml · nonDerivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,061 Read SEC document |
| June 08, 2018 Filed Jun 14, 2018 00:45 UTC Amendment |
Tennant StanleyDirector
|
PurchaseCommon Stock | 10,000 | $0.80 | $8,000.00 |
DisclosureSEC source: 0000899243-18-016468 · doc4a.xml · nonDerivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,839 Read SEC document |
| June 08, 2018 Filed Jun 14, 2018 00:40 UTC Amendment |
BRANCACCIO JOHN PDirector
|
PurchaseCommon Stock | 10,000 | $0.80 | $8,000.00 |
DisclosureSEC source: 0000899243-18-016465 · doc4a.xml · nonDerivative · entry 1 BRANCACCIO JOHN P · CIK 0001276551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,598 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:30 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002487 · doc4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 90,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On April 7, 2017, the reporting person was granted 90,000 restricted stock units, all of which vested on January 30, 2018. The common stock into which such vested restricted stock units converted on January 30, 2018 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On April 7, 2017, the reporting person was granted 90,000 restricted stock units, all of which vested on January 30, 2018. The common stock into which such vested restricted stock units converted on January 30, 2018 is reported in Table I on this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.